S&P 500
5.222,68 +94,89 (+1,85%) Nasdaq
16.340,87 +184,57 (+1,14%) NIKKEI 225
38.243,59 +14,48 (+0,04%) Dólar/Euro
1,0774 +0,0001 (+0,01%) Petróleo Brent
82,53 -0,26 (-0,31%) Bitcoin EUR
56.443,13 -103,43 (-0,18%)
OncoSec Medical Incorporated (ONCSQ)
OncoSec Medical Incorporated
24 North Main Street
Pennington, NJ 08534
United States
855 662 6732
https://oncosec.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 40
Descripción
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey. On June 14, 2023, OncoSec Medical Incorporated filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of New Jersey.
Gobierno corporativo
El ISS Governance QualityScore de OncoSec Medical Incorporated, a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
